Medilink Therapeutics (suzhou) Co., Ltd.

This study tests an experimental drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers that have not responded to other treatments. The main goal is to see if the drug can shrink tumors, while also checking for side eff…

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer that has spread. The goal is to find safe doses and see if the combination helps control the cancer. About 118 adults will take part, and treatment continues until t…

This study tests a new drug (YL201) combined with ivonescimab in 260 adults with advanced solid tumors, including lung cancers. The goal is to see if the combination is safe and can shrink tumors. Participants must have good organ function and not be eligible for local curative t…

This early-phase study tests a new drug, YL211, in about 155 adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; second, confirming that dose; and third, checking how well it works. The main goal…

This study tests a new drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried other treat…

This study tests a new drug (YL201) combined with an immunotherapy (toripalimab), with or without chemotherapy (cisplatin), in people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combination is safe and helps control the cancer. About 202 adults …

This study tests a new drug called YL205 in 252 adults with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants receive YL205 and are closely monitored for s…

This study tests a new drug called YL242, given alone or with other treatments, in people with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 adults will take part across multiple sites.

This early-phase study tests a new drug called YL217 in about 220 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will also monitor side effects and how the dr…

This early-phase study tests a new drug called YL201, alone or with other cancer treatments, in about 312 adults with advanced solid tumors that have stopped responding to standard therapies. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two…

This study tests a new drug called YL202 combined with other cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to find a safe dose and see if the combination shrinks tumors. About 414 adults aged 18-75 who have tried standard tr…